We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
Internal Medicine - Allegheny General Hospital/Medical College of Pennsylvania
Fellowships
Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist and work as part of a multidisciplinary team to care for patients with breast cancer.
In my clinical research, I focus on developing more-effective and less-toxic treatment strategies for women with this disease. My particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.
Read more
My research has changed standard practice. For example, the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer was a direct consequence of an investigator-initiated trial that I led at Memorial Sloan Kettering. Additionally, I led another investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer. This led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. I am currently leading other research trials, both locally and internationally. From these studies and others, I have also focused on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, I am studying cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.
New therapies have greatly improved the prognosis for many breast cancer patients, but some treatments produce side effects that appear years after the completion of treatment. My colleagues and I are working to develop markers or predictors to identify the patients who may be at risk of developing early, and possibly late, complications such as heart damage so that we can design early interventions to prevent these side effects — for example, by adding a cardiac drug to treatment to minimize heart problems in the future.
Awards and Honors
Exceptional Women in Medicine Award, Castle Connolly (2023)
Castle Connolly: America's Top Doctors (2023)
Castle Connolly: New York Magazine Top Doctors (2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Dang’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Chau T. Dang discloses the following relationships and financial interests:
Daiichi Sankyo Provision of Services
Gilead Pharmaceutical Provision of Services
Novartis Provision of Services
Pfizer, Inc. Provision of Services
Seattle Genetics Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
